Duration of therapy for chronic pulmonary aspergillosis (CPA)
| Population | Intention | Intervention | SoR | QoE | Ref. | Comment |
| CPA patients on antifungal therapy | Control of infection, arrest of pulmonary fibrosis, prevention of haemoptysis, improved quality of life | 6 months of antifungal therapy | B | II | [15, 30, 31, 59, 83, 89, 96] | Optimal duration of therapy in CPA is unknown, indefinite suppressive therapy may be appropriate in selected patients |
| Long-term antifungal therapy, depending on status and drug tolerance | C | III | [15, 30, 89, 59] | |||
| SAIA/CNPA | Cure | 6 months | B | II | [15, 30] | Longer durations may be necessary in those with continuing immunosuppression |
SoR: strength of recommendation; QoE: quality of evidence; SAIA: subacute invasive aspergillosis; CNPA: chronic necrotising pulmonary aspergillosis.